Vicore Pharma (NASDAQ:VCRE) Announces Quarterly Earnings Results

Vicore Pharma (NASDAQ:VCRE) announced its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, FiscalAI reports. The business had revenue of $0.06 million for the quarter.

Vicore Pharma Stock Performance

VCRE opened at $10.01 on Friday. Vicore Pharma has a 52-week low of $7.88 and a 52-week high of $17.80.

Wall Street Analyst Weigh In

A number of research firms have commented on VCRE. Weiss Ratings initiated coverage on shares of Vicore Pharma in a research report on Thursday, October 8th. They set a “sell (e-)” rating on the stock. Chardan Capital assumed coverage on Vicore Pharma in a research report on Wednesday. They issued a “buy” rating and a $15.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a research note on Friday, October 9th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vicore Pharma presently has a consensus rating of “Hold” and an average target price of $20.00.

Vicore Pharma Company Profile

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.

Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.